How a Catheter Fragment Causes Persistent Infection
Foreign bodies in the bloodstream — including fractured catheter fragments — are rapidly colonized by bacteria that adhere to the polymer surface and produce a polysaccharide matrix called a biofilm. Biofilm-encased bacteria are protected from both the immune system's phagocytic cells and antibiotic penetration, making infections associated with intravascular foreign bodies notoriously refractory to antibiotic treatment alone. The biofilm continuously sheds planktonic (free-floating) bacteria into the bloodstream, causing persistent or relapsing bacteremia that returns each time antibiotic therapy is discontinued.
Staphylococcus aureus (including methicillin-resistant S. aureus, MRSA) and coagulase-negative staphylococci (such as S. epidermidis) are the organisms most commonly associated with catheter-related foreign body infections. S. aureus bacteremia is particularly dangerous because it carries a high rate of metastatic infection — seeding bacteria to distant sites including the heart valves (endocarditis), bones (osteomyelitis), joints (septic arthritis), kidneys (renal abscess), and brain (cerebral abscess). Each of these metastatic complications represents an additional organ system injury with its own treatment course and long-term consequences.
Infective Endocarditis — The Cardiac Infection Complication
Infective endocarditis (IE) occurs when bacteria from a catheter fragment colonize the endothelial lining of the heart valves, forming bulky vegetations on the valve leaflets. Because fractured PowerPort catheter fragments typically reside in the right heart, the tricuspid and pulmonary valves are at particular risk. Tricuspid valve endocarditis causes valvular regurgitation (backward leakage of blood) and may require cardiac surgery for valve repair or replacement. Septic pulmonary emboli — vegetations that break off and travel to the lungs — cause multiple areas of pulmonary infarction, presenting as fever, chest pain, and new pulmonary infiltrates on imaging.
Treatment of catheter-related endocarditis requires 6 weeks of intravenous antibiotics per American Heart Association guidelines, typically administered through a peripherally inserted central catheter in the outpatient setting after initial hospital stabilization. Patients with refractory endocarditis, severe valvular destruction, or persistent bacteremia despite antibiotics require cardiac surgery. The physical and psychological toll of endocarditis — prolonged IV antibiotic therapy, surgical risk, extended recovery, and the fear of relapse — are all components of compensable damages in a PowerPort lawsuit.
Heightened Risk for Immunocompromised Cancer Patients
The population most likely to have a PowerPort implanted — cancer patients receiving chemotherapy — is precisely the population at highest risk for serious infectious complications from a catheter fracture. Chemotherapy agents destroy rapidly dividing cells including neutrophils, the white blood cells primarily responsible for bacterial killing. Neutropenic (low white blood cell count) patients have dramatically impaired ability to contain bacteremia, making infections that a healthy person might control rapidly life-threatening in chemotherapy patients. Many PowerPort fracture victims are cancer survivors who believed their cancer battle was behind them, only to face a life-threatening infection years later from a device they trusted for their treatment.
Frequently Asked Questions
Related Pages
PowerPort Catheter Fracture — How It Happens
Bard PowerPort catheters fracture through a well-documented mechanism called environmental stress cracking (ESC) of polyurethane — a process that was scientifically foreseeable at the time of device design. The fracture is silent and painless, meaning most patients have no idea their catheter has broken until complications force diagnostic imaging.
PowerPort MDL Settlement Timeline — What to Expect
MDL mass tort litigation follows a predictable multi-year progression from case filing through bellwether trials to global settlement. Understanding each phase helps PowerPort plaintiffs set realistic expectations for timing and the factors that determine individual settlement amounts.
PowerPort Catheter Migration — Where Fragments Go
When a PowerPort catheter fractures, the free fragment enters the central venous circulation and travels to the heart and lungs following the path of venous blood flow. The fragment's final resting location determines the severity of injury — from retrievable right-heart positions to life-threatening peripheral pulmonary artery lodgment.
Bard PowerPort MDL in the District of Arizona
MDL No. 3:22-md-03062 in the U.S. District Court for the District of Arizona is the central federal forum for all Bard PowerPort catheter fracture cases. Understanding how the MDL works, where it currently stands, and what participation means for individual plaintiffs is essential for anyone considering a PowerPort lawsuit.
PowerPort vs. Other Port Catheters — Key Differences
The Bard PowerPort's polyurethane catheter is the defining design characteristic that distinguishes it from safer alternatives like Hickman catheters, silicone Mediport devices, and PICC lines — none of which use polyurethane tubing and none of which carry the same environmental stress cracking fracture risk.
PowerPort Removal Surgery — How Fractured Catheters Are Retrieved
Retrieval of a fractured PowerPort catheter fragment requires either percutaneous cardiac catheterization or open thoracic surgery, depending on fragment location and accessibility. The retrieval procedure itself carries procedural risks, and failure to retrieve leaves the patient with an ongoing foreign body infection and cardiac risk.
PowerPort Cardiac Perforation — Heart Surgery Risk
Cardiac perforation by a fractured PowerPort catheter fragment is a life-threatening emergency. The thin-walled right ventricle is particularly vulnerable to penetration by a fragment's sharp edge, causing cardiac tamponade — a surgical emergency that can be fatal within minutes without treatment.
Becton Dickinson Liability — BD's Acquisition of Bard
Becton, Dickinson and Company (BD) acquired C.R. Bard in 2017 for $24 billion and assumed full corporate liability for all Bard product claims, including the PowerPort. BD now faces claims not only for Bard's pre-acquisition conduct but also for BD's own post-acquisition decisions to continue selling the PowerPort without redesigning or adequately warning about the fracture risk.
PowerPort Evidence and Records — What You Need for Your Case
Building a strong PowerPort catheter lawsuit requires gathering specific categories of medical and device records. Even if you no longer have the physical device, documentary evidence of the fracture, fragment location, and resulting injury is sufficient to support a claim.
Bard PowerPort Catheter Lawsuit
The Bard PowerPort is an implantable venous access device — a small port placed under the skin, typically in the chest — that allows medical professionals to administer chemotherapy, draw blood, and deliver medications without repeated needle sticks. Millions of patients have received PowerPort devices since C.R. Bard introduced them in the 1990s. The devices are especially common among cancer patients who require long-term intravenous access. Beginning in the early 2010s, patients, physicians, and researchers began documenting a disturbing pattern: the polyurethane catheter tubing attached to the port was fracturing inside the body. Fragments of the catheter — sometimes several centimeters long — were entering the bloodstream and migrating toward the heart and lungs. The resulting complications range from serious to fatal: cardiac perforation, cardiac tamponade, pulmonary embolism, sepsis, and endocarditis. Becton Dickinson (BD) acquired C.R. Bard in 2017 for $24 billion, inheriting both the PowerPort product line and the mounting litigation. In 2022, a federal multidistrict litigation was established in the U.S. District Court for the District of Arizona to consolidate cases nationwide. Legal claims proceed under theories of design defect, manufacturing defect, failure to warn, and negligence. Patients who received a PowerPort catheter and subsequently experienced catheter fracture, fragment migration, infection, cardiac complications, or unexplained symptoms may be entitled to substantial compensation.
View full case overview